Abstract
A 50-year-old woman was hospitalized for fainting caused by hypoglycemia. Her blood glucose level was low (40 mg/dL), immunoreactive insulin was 16.9 μU/mL, and C-peptide level was high (4.8 ng/mL). Computed tomography and magnetic resonance imaging revealed a 7-mm tumor in the uncinate process of the pancreas. A selective arterial calcium injection test indicated an increase in the superior mesenteric artery. Insulinoma of the uncinate process of the pancreas was diagnosed, and tumor enucleation was planned using an artificial pancreas for intraoperative and postoperative blood glucose control. Hypoglycemia (blood glucose, 38 mg/dL) was observed from the onset of surgery. An artificial pancreas cannot be used if the blood glucose level is ≤ 70 mg/dL; thus, continuous glucose infusion was administered. The sudden rise in blood glucose prompted insulin infusion from the device, causing hypoglycemia. Controlling blood glucose levels is challenging when introducing the artificial pancreas. However, altering the device’s blood glucose control algorithm controlled the fluctuating blood glucose level, and, intraoperative average blood glucose was raised to 94.8 ± 21.1 mg/dL, thereby avoiding hypoglycemia, that is, a blood glucose level of ≤ 70 mg/dL. We report a case in which an artificial pancreas was used for glycemic control during surgery for an insulinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and materials
All the data generated or analyzed during this study are included within the article.
References
Katsuyama N, Osugi M. New artificial pancreas (bedside type). Diabetes. 2010;38:41–5.
Soyama A, Kugiyama T, Hara T, et al. Efficacy of an artificial pancreas device for achieving tight perioperative glycemic control in living donor liver transplantation. Artif Organs. 2019;43:270–7.
Yoshimoto T, Ikemoto T, Morine Y, et al. Impact of using a perioperative artificial endocrine pancreas in pancreatic resection. Ann Gastroenterol Surg. 2020;4:591–6.
Okabayashi T, Nishimori I, Maeda H, et al. Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: a prospective randomized clinical trial. Diabetes Care. 2009;32:1425–7.
Hanazaki K, Yatabe T, Kobayashi M, et al. Perioperative glycemic control using an artificial endocrine pancreas in patients undergoing total pancreatectomy: tight glycemic control may be justified in order to avoid brittle diabetes. Bio Med Mater Eng. 2013;23:109–16.
Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783–98.
Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19:829–37.
Isachi H, Kato K, Tanigawa H. Diagnosis and surgical treatment of pancreatic endocrine tumors. Clin Pathol. 1994;42:150–9.
Soga J, Yukawa Y. Pancreatic Endocrinomas: a statistical analysis of 1857 cases. J Hep Bil Pancr Surg. 1994;1:522–9.
Nosue H, Kamoda T, Aoki K, et al. A case of an insulinoma girl who was able to temporarily control blood glucose with diazoxide. Pediatr Clin. 2010;63:1027–32.
Ippai I, Toshiaki H, Izumi Y, et al. A case of insulinoma in which subcutaneous injection of otocreotide was useful for preoperative hypoglycemia control. Jpn J Gastroenterol. 2014;47:596–601.
Sugiyama Y, Kiuchi C, Suzuki M, et al. Glucose management during insulinoma resection using real-time subcutaneous continuous glucose monitoring. Case Rep Anesthesiol. 2018;2018:6248467.
Pulver JJ, Cullen BF, Miller DR, et al. Use of the artificial beta cell during anesthesia for surgical removal of an insulinoma. Anesth Analg. 1980;59:950–2.
Valenta LJ, Eisenberg H, Miller DR, et al. The value of artificial beta cell in the management of insulinoma. West J Med. 1982;137:67–75.
Manabe M, Morimatsu H, Egi M, et al. Anesthetic management of pediatric patients with insulinoma using continuous glucose monitoring (in Japanese with English abstract). Masui. 2009;58:757–9.
Hirose K, Kawahito S, Mita N, et al. Usefulness of artificial endocrine pancreas during resection of insulinoma. J Med Invest. 2014;61:421–5.
Ohira H, Asano T, Kinoshita Y. Looking back on the history of artificial pancreas development. Artif Organs. 2019;48:173–5.
Author information
Authors and Affiliations
Contributions
YA analyzed and drafted the manuscript. HK and AH participated in the data collection and assisted with data interpretation. SA, MI, MS, DK, CH, TK, and TH reviewed and revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Asano, Y., Kato, H., Arakawa, S. et al. Experience with intraoperative use of artificial pancreas during local resection of insulinoma. Clin J Gastroenterol 15, 1012–1017 (2022). https://doi.org/10.1007/s12328-022-01679-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-022-01679-5